ES2526705T3 - Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados - Google Patents

Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados Download PDF

Info

Publication number
ES2526705T3
ES2526705T3 ES06826778.0T ES06826778T ES2526705T3 ES 2526705 T3 ES2526705 T3 ES 2526705T3 ES 06826778 T ES06826778 T ES 06826778T ES 2526705 T3 ES2526705 T3 ES 2526705T3
Authority
ES
Spain
Prior art keywords
mice
losartan
tgf
muscle
fbn1c1039g
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06826778.0T
Other languages
English (en)
Spanish (es)
Inventor
Harry C. Dietz
Daniel P. Judge
Enid R. Neptune
Ronald Cohn
Jennifer Habashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2526705T3 publication Critical patent/ES2526705T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
ES06826778.0T 2005-10-25 2006-10-25 Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados Active ES2526705T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72997605P 2005-10-25 2005-10-25
US729976P 2005-10-25
PCT/US2006/041846 WO2007050793A2 (en) 2005-10-25 2006-10-25 Methods and compositions for the treatment of marfan syndrome and associated disorders

Publications (1)

Publication Number Publication Date
ES2526705T3 true ES2526705T3 (es) 2015-01-14

Family

ID=37968564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06826778.0T Active ES2526705T3 (es) 2005-10-25 2006-10-25 Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados

Country Status (5)

Country Link
US (1) US8597646B2 (cg-RX-API-DMAC7.html)
EP (2) EP2862867A3 (cg-RX-API-DMAC7.html)
JP (1) JP5602365B2 (cg-RX-API-DMAC7.html)
ES (1) ES2526705T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007050793A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5470261B2 (ja) * 2007-11-02 2014-04-16 アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) 大動脈瘤非ヒト動物モデルの作出方法
US9567637B2 (en) 2009-04-20 2017-02-14 The University Of Tokyo Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease
EP2482817A1 (en) * 2009-10-01 2012-08-08 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
RU2456925C1 (ru) * 2011-03-15 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития идиопатического сколиоза у детей
US20140148498A1 (en) * 2011-04-14 2014-05-29 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2013078261A1 (en) * 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
JP6240379B2 (ja) * 2012-10-06 2017-11-29 株式会社 バイオエルティ 循環型TGF−βの抑制剤
US20150284455A1 (en) * 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
JP6495884B2 (ja) 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗tgfベータ抗体および抗原結合フラグメント
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
WO2018160987A1 (en) * 2017-03-02 2018-09-07 The Johns Hopkins University Map kinase pathway targets for the treatment of marfan syndrome
US11273148B2 (en) 2017-09-01 2022-03-15 The Johns Hopkins University Targeted epigenetic therapy for inherited aortic aneurysm condition
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
AU2021409832A1 (en) * 2020-12-23 2023-08-10 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-β SIGNALING AND USE THEREOF
JP2025529287A (ja) * 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (ja) 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
AU673506B2 (en) 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
JP3854307B2 (ja) 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019177A1 (en) 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
JPH08504577A (ja) 1992-10-30 1996-05-21 エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ TGF−βの制御活性を改変するための組成物および方法
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
DE69429617T2 (de) 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
DE69523750T2 (de) 1994-05-04 2002-08-01 Mount Sinai Hospital Corp., Toronto Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5912224A (en) 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
DE69739071D1 (de) 1996-07-24 2008-12-11 Chugai Pharmaceutical Co Ltd Menschliche tak1 und für diese kodierende dna
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
AU7357996A (en) 1996-08-16 1998-03-06 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6017755A (en) 1996-08-22 2000-01-25 Hsc Research & Development Limited MADR2 tumour suppressor gene
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
JPH10114676A (ja) * 1996-10-09 1998-05-06 Toray Ind Inc β型トランスフォーミング増殖因子産生抑制剤
DE69734894T2 (de) 1996-10-25 2006-07-20 Ethicon, Inc. Testverfahren für antifibrotischen wirkstoff
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
CN1257545A (zh) 1997-04-18 2000-06-21 拜奥根有限公司 Ⅱ型TGF-β受体/免疫球蛋白恒定区融合蛋白
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
US6251628B1 (en) 1997-05-20 2001-06-26 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding Smad7
WO1998053830A1 (en) 1997-05-28 1998-12-03 President And Fellows Of Harvard College METHODS AND REAGENTS FOR MODULATING TGF-β SUPERFAMILY SIGNALING
JP4108768B2 (ja) 1997-06-02 2008-06-25 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) Smad相互作用ポリペプチド及びそれらの使用
CA2292339A1 (en) 1997-06-13 1998-12-17 Ludwig Institute For Cancer Research Smad6 and uses thereof
IL138692A0 (en) 1998-03-27 2001-10-31 Lilly Co Eli Treatment and prevention of vascular disease
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
WO2004010929A2 (en) * 2002-07-25 2004-02-05 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
WO2005004913A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
SG145713A1 (en) * 2003-08-13 2008-09-29 Univ Illinois SILENCING OF TGFss TYPE II RECEPTOR EXPRESSION BY SIRNA
US7462185B1 (en) * 2004-12-23 2008-12-09 Cardican Inc. Intravascular stapling tool
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
WO2007050793A2 (en) 2007-05-03
EP2862867A3 (en) 2015-08-05
US20100034806A1 (en) 2010-02-11
EP2862867A2 (en) 2015-04-22
WO2007050793A3 (en) 2008-01-24
US8597646B2 (en) 2013-12-03
EP1948675A2 (en) 2008-07-30
EP1948675A4 (en) 2009-09-23
EP1948675B1 (en) 2014-07-30
JP5602365B2 (ja) 2014-10-08
JP2009513663A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
EP1948675B1 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
Zoetis et al. Species comparison of anatomical and functional renal development
Delpire et al. Na+‐K+‐2Cl− cotransporter (NKCC) physiological function in nonpolarized cells and transporting epithelia
Eggers et al. Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots
Saigusa et al. Molecular pathways and therapies in autosomal-dominant polycystic kidney disease
ES2764480T3 (es) Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
Romaniello et al. Aortopathy in Marfan syndrome: an update
ES2714373T3 (es) Anticuerpo específico de endoglina para uso en un método de tratamiento de la insuficiencia cardíaca y de afecciones relacionadas
KR101953736B1 (ko) 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물
ES2538265T3 (es) Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
ES2397637T3 (es) Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico
JP7057976B2 (ja) 被験体において胸部大動脈瘤(TAA)を同定するin vitro方法
Galata et al. Amelioration of desmin network defects by αB-crystallin overexpression confers cardioprotection in a mouse model of dilated cardiomyopathy caused by LMNA gene mutation
US20110244059A1 (en) Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
US12478634B2 (en) Compositions and methods for treating muscular dystrophy and other disorders
Huang et al. Hydrogen sulfide alleviates heart failure with preserved ejection fraction in mice by targeting mitochondrial abnormalities via PGC-1α
US9751950B2 (en) Methods of reducing skeletal muscle loss using an antibody against Fn14
US20200289482A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
ES2955158T3 (es) Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2
Lao et al. Lmo7 is dispensable for skeletal muscle and cardiac function
ES2750125T3 (es) ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares
Masyuk et al. Polycystic Liver Diseases: genetics, Mechanisms, and Therapies
WO2008157753A1 (en) Methods of treatment for spinal muscular atrophy
US20110268736A1 (en) Method for treating congenital myopathy
CN119095962A (zh) 治疗杜氏肌营养不良的方法